Paragon Biosciences is a biotechnology incubator and an investment organization which was established with a significant purpose of helping individuals with an illness that lack treatment options or therapies. Jeff Aronin is the Chief Executive Officer of Paragon Biosciences and is known for his commitment to helping those suffering from rare diseases. Paragon’s portfolio companies use advanced research methods to discover new innovative approaches to developing treatments and medication. Ever since the founding of Paragon Biosciences, they have invested heavily in helping their portfolio companies exceed. Despite the groundbreaking techniques for treatment studied and used in the medical industry, Jeff Aronin wants to make a difference in the industry by taking innovation and biotechnology to higher levels.
Through Paragon Biosciences, Mr. Aronin has been using his innovative approach and experience to heighten medical conceptualization for treating patients with rare diseases. Jeff believes that one needs to go beyond the current idea to treat conditions. Paragon Biosciences works together with a team of experienced researchers and who are passionate about studying new treatment methods. Paragon also aids its portfolio companies in ensuring they are staffed with world-class researchers and medical experts who are dedicated to developing innovative treatments for a specified illness. Each of the organizations is independently led although they are part of the Paragon Biosciences portfolio of companies. Paragon Biosciences is a known name in the biotechnology industry and through Jeff’s Aronin leadership and his team of researchers and experts they have overseen the development of 14 drugs which have been approved by the United States Food and Drugs Administration (FDA).
For over 20 years Jeff Aronin has been working in the biotechnology industry. Jeff Aronin is passionate about biotechnology and even though his organization prides itself on being among the top companies in the industry, Jeff is not satisfied simply by FDA approvals. He’s more concerned with the lives of the people those drugs help improve or save. Mr. Aronin has invested heavily in research and development of novel drugs and is committed to helping patients in need.